Overview
At a Glance
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that potently stimulates growth hormone secretion by activating the ghrelin receptor. It has been used clinically as a diagnostic tool for growth hormone deficiency and is one of the most studied GH secretagogues. It also raises cortisol and prolactin to some degree, unlike more selective alternatives like ipamorelin. It is not FDA-approved for therapeutic use and is available as a research chemical.
GHRP-2 (Growth Hormone Releasing Peptide-2), also known by the INN pralmorelin, is a synthetic hexapeptide that stimulates the release of growth hormone (GH) from the anterior pituitary gland. It belongs to the growth hormone secretagogue (GHS) class of compounds, which act by binding to the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary (Bowers et al., 1998).
GHRP-2 was developed in the 1990s as part of a broader research effort to identify synthetic molecules capable of stimulating endogenous GH release. It emerged from structure-activity relationship studies on enkephalin-derived peptides, which unexpectedly demonstrated GH-releasing properties. Among the GHRP family (GHRP-1, GHRP-2, GHRP-6, hexarelin), GHRP-2 is considered one of the most potent stimulators of GH secretion on a per-microgram basis (Bowers, 2001).
Unlike Ipamorelin — a more selective GHS — GHRP-2 also stimulates the release of cortisol and prolactin at higher doses, making it less selective in its endocrine effects. This characteristic distinguishes it from newer-generation GH secretagogues and is an important consideration for clinical use (Bowers et al., 1998).
GHRP-2 has been approved in Japan (as pralmorelin) for diagnostic use in evaluating growth hormone deficiency. It has undergone Phase 1 and Phase 2 clinical trials in various countries. It is not FDA-approved for any therapeutic indication in the United States. It remains widely available through research chemical suppliers.
Quick Facts
| Property | Details |
|---|---|
| Molecular formula | C₄₅H₅₅N₉O₆ |
| Amino acid sequence | D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH₂ |
| Molecular weight | ~817.97 Da |
| Receptor target | Growth hormone secretagogue receptor (GHS-R1a) |
| Routes studied | Subcutaneous injection, intravenous, intranasal |
| Human trials | Phase 1–2 completed; approved in Japan for diagnostic use |
| FDA approval | None |
| WADA status | Prohibited (S2 — Peptide Hormones, Growth Factors) |
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
How It Works
GHRP-2 acts primarily through the ghrelin/growth hormone secretagogue receptor (GHS-R1a), a G protein-coupled receptor expressed in the hypothalamus, pituitary gland, and other tissues. Activation of this receptor triggers a signaling cascade that culminates in growth hormone release from somatotroph cells in the anterior pituitary (Bowers et al., 1998).
GHS-R1a Receptor Activation
The GHS-R1a receptor is the same receptor targeted by ghrelin, the endogenous "hunger hormone" produced primarily by the stomach. When GHRP-2 binds to GHS-R1a, it activates phospholipase C signaling, leading to increased intracellular calcium and subsequent GH vesicle exocytosis. GHRP-2 acts at both the hypothalamic level (stimulating GHRH release and suppressing somatostatin) and directly at the pituitary level (Bowers, 2001).
Synergy with GHRH
GHRP-2 and growth hormone-releasing hormone (GHRH) act through complementary mechanisms. GHRH activates the GHRH receptor (a distinct receptor from GHS-R1a), stimulating GH gene transcription and release via the cAMP/PKA pathway. When GHRP-2 is administered alongside GHRH or a GHRH analog (such as CJC-1295 or modified GRF 1-29), the GH response is synergistic — substantially greater than either compound alone. Studies have demonstrated that the combined GH release can be 3–5 times greater than GHRP-2 or GHRH administered independently (Bowers et al., 1998).
GH Pulsatility
GH secretion in healthy individuals follows a pulsatile pattern, with the largest pulses occurring during deep sleep. GHRP-2 amplifies this natural pulsatile release rather than producing a flat, sustained GH elevation. This distinction is physiologically relevant: pulsatile GH release is associated with the beneficial downstream effects of GH (lipolysis, protein synthesis, tissue repair), while continuous GH elevation can lead to receptor desensitization and adverse metabolic effects (Bowers, 2001).
Cortisol and Prolactin Effects
Unlike more selective GH secretagogues (e.g., Ipamorelin), GHRP-2 stimulates the release of cortisol and prolactin at higher doses. This effect is dose-dependent:
- Cortisol: GHRP-2 stimulates ACTH release, leading to transient cortisol elevation. At doses of 100 mcg, this effect is generally mild. At doses above 200–300 mcg, cortisol increases become more clinically significant (Bowers et al., 1998).
- Prolactin: GHRP-2 produces a modest, transient prolactin increase. This is typically not clinically significant at standard doses but may become relevant with chronic high-dose use (Arvat et al., 2001).
Appetite Stimulation
As a ghrelin receptor agonist, GHRP-2 stimulates appetite through the same pathways as endogenous ghrelin. This effect is moderate compared to GHRP-6 (which produces stronger appetite stimulation) but more pronounced than Ipamorelin. The appetite stimulation is mediated through hypothalamic GHS-R1a activation, which modulates neuropeptide Y (NPY) and agouti-related peptide (AgRP) signaling (Muccioli et al., 2007).
IGF-1 Elevation
The GH released in response to GHRP-2 stimulates hepatic production of insulin-like growth factor-1 (IGF-1). IGF-1 mediates many of the downstream anabolic and tissue-repair effects attributed to GH, including protein synthesis, cell proliferation, and inhibition of apoptosis. Sustained GHRP-2 use leads to elevated IGF-1 levels, which can be monitored via blood testing (Bowers, 2001).
Go Deeper
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Research
GH Stimulation Studies
Multiple controlled human studies have characterized GHRP-2's GH-releasing properties:
- Dose-response: Intravenous GHRP-2 at 1 mcg/kg produces robust GH peaks in healthy subjects, with dose-dependent increases up to a plateau. The GH response is blunted in obesity and enhanced in lean individuals (Bowers et al., 1998).
- Subcutaneous pharmacokinetics: Subcutaneous administration produces a GH peak within 15–60 minutes, with return to baseline by 2–3 hours. The magnitude of the GH pulse varies by individual, age, body composition, and concurrent GHRH status (Bowers, 2001).
- Synergy with GHRH: Co-administration of GHRP-2 with GHRH produces a synergistic GH response 3–5 times greater than either agent alone. This synergy has been well-documented in human studies and forms the basis for combined protocols (Arvat et al., 2001).
- Elderly subjects: GHRP-2 effectively stimulates GH release in elderly subjects, partially restoring the diminished GH secretion associated with aging (somatopause). The response is reduced compared to younger subjects but remains clinically meaningful (Broglio et al., 2003).
Diagnostic Use (Japan)
GHRP-2 (pralmorelin) is approved in Japan as a diagnostic agent for evaluating GH deficiency. In this application, a single intravenous dose is administered and serial GH levels are measured over 60–120 minutes. The test distinguishes GH-deficient patients from healthy subjects based on the magnitude of the GH response. Clinical studies supporting this approval demonstrated high sensitivity and specificity for GH deficiency diagnosis (Kojima et al., 2006).
Body Composition
- Lean mass and fat mass: Short-term studies (weeks to months) of GHRP-2 in healthy volunteers and GH-deficient populations have shown trends toward increased lean body mass and decreased fat mass, consistent with GH's known metabolic effects. However, large-scale, long-term body composition trials have not been conducted (Bowers, 2001).
- Visceral adiposity: GH stimulation via GHRP-2 may preferentially reduce visceral fat, based on the established relationship between GH action and visceral adipose tissue metabolism. Direct evidence for GHRP-2 specifically on visceral fat is limited to small studies (Arvat et al., 2001).
Sleep and GH Secretion
GH secretion is closely linked to sleep architecture, with the largest GH pulses occurring during slow-wave sleep (SWS). GHRP-2 administered before sleep enhances the nocturnal GH pulse. Studies have examined whether this enhancement affects sleep quality, with some data suggesting modest improvement in sleep architecture — though this remains a preliminary finding (Bowers, 2001).
Cardioprotection
Preclinical studies have demonstrated cardioprotective effects of GHRP-2 independent of GH release. In animal models of myocardial ischemia-reperfusion injury, GHRP-2 reduced infarct size and improved cardiac function. These effects appear to be mediated through GHS-R1a-dependent anti-apoptotic and anti-inflammatory pathways in cardiac tissue (Muccioli et al., 2007).
Comparison with Other GH Secretagogues
| Compound | GH Release Potency | Cortisol Effect | Prolactin Effect | Appetite Stimulation |
|---|---|---|---|---|
| GHRP-2 | High | Moderate (dose-dependent) | Mild-moderate | Moderate |
| GHRP-6 | Moderate-high | Moderate | Mild-moderate | Strong |
| Ipamorelin | Moderate | Minimal | Minimal | Minimal |
| Hexarelin | High | Moderate-high | Moderate | Moderate |
Limitations of the Research
- No Phase 3 therapeutic trials: While Phase 1–2 data and the Japanese diagnostic approval provide meaningful human data, no large-scale efficacy trials for therapeutic applications (anti-aging, body composition, injury healing) have been completed.
- Short study durations: Most human studies are acute (single dose) or short-term (days to weeks). Long-term safety and efficacy data from controlled trials are lacking.
- Desensitization questions: The degree to which chronic GHRP-2 use leads to GHS-R1a desensitization and diminished GH response over time remains incompletely characterized.
- Population specificity: GH response to GHRP-2 varies significantly by age, body composition, and underlying GH axis status, making generalization difficult.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Uses
Approved Use
GH deficiency diagnosis (Japan): GHRP-2 (pralmorelin) is approved as a diagnostic provocative test for GH deficiency. A single intravenous dose is administered, and serial GH measurements determine the adequacy of pituitary GH reserve (Kojima et al., 2006).
Off-Label and Research Applications
The following applications are reported in clinical practice and research settings. None are FDA-approved indications.
| Application | Evidence Basis | Notes |
|---|---|---|
| GH optimization / anti-aging | Phase 1–2 human data | Used to stimulate endogenous GH production in individuals with age-related GH decline. Intended as an alternative to exogenous GH administration. |
| Body composition | Limited human data | Used to support fat loss and lean mass preservation through GH-mediated metabolic effects. |
| Injury recovery | Indirect (GH/IGF-1 mediated) | GH and IGF-1 play established roles in tissue repair. GHRP-2 is used to elevate these factors as adjunctive support during recovery from musculoskeletal injuries. |
| Sleep optimization | Preliminary human data | Administered before sleep to enhance nocturnal GH pulsatility. Some reports suggest improved sleep quality. |
| GH deficiency (therapeutic) | Phase 1–2 data | Investigated as a potential alternative to daily GH injections for GH-deficient patients. Not approved for this use. |
What GHRP-2 Is NOT Used For
- Direct muscle building: GHRP-2 is not an anabolic steroid. While GH elevation supports protein synthesis, GHRP-2 does not directly increase testosterone or produce androgenic effects.
- Weight loss medication: Although GH has lipolytic effects, GHRP-2 also stimulates appetite, which may partially offset any fat-loss benefit in some individuals.
- Growth promotion in children: GHRP-2 has not been studied or approved for pediatric growth disorders.
- Replacement for standard medical care: GHRP-2 should be considered as a potential adjunct, not a replacement for established treatments for GH deficiency or other conditions.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Dosing
GHRP-2 is not FDA-approved for therapeutic use. No official therapeutic dosing guidelines exist. The information below reflects protocols commonly reported in clinical practice and research literature — it is provided for informational purposes only. Do not self-administer any peptide without guidance from a qualified healthcare provider. Dosing, preparation, and administration should be overseen by a licensed clinician.
Commonly Reported Protocols
| Protocol | Typical Dose | Frequency | Notes |
|---|---|---|---|
| Standard GH stimulation | 100–300 mcg SC | 2–3x daily | Administered on an empty stomach (fasting for 1–2 hours before and 30 minutes after). Timed to amplify natural GH pulses: morning, post-workout, and before sleep. |
| Conservative / entry | 100 mcg SC | 1–2x daily | Lower dose to minimize cortisol and prolactin elevation while still achieving GH stimulation. |
| Combined with GHRH analog | 100–200 mcg GHRP-2 + 100 mcg mod GRF 1-29 | 2–3x daily | Synergistic protocol. Produces significantly greater GH release than either compound alone. |
| Diagnostic (Japan) | 100 mcg IV (single dose) | Once | Approved diagnostic protocol. GH levels measured at 15, 30, 45, 60 minutes post-administration. |
Sources: Bowers et al. (1998) — dose-response characterization; Arvat et al. (2001) — endocrine dose-response in humans.
Timing Considerations
- Fasting state: GH release in response to GHRP-2 is significantly blunted by elevated blood glucose and insulin. Administration on an empty stomach (minimum 1–2 hours post-meal) is considered important for efficacy.
- Pre-sleep dose: The pre-sleep administration is designed to enhance the natural nocturnal GH surge that occurs during slow-wave sleep.
- Post-exercise dose: Some protocols include a post-workout dose to augment the exercise-induced GH pulse.
- Spacing: Doses are typically separated by at least 3 hours to allow GH levels to return to baseline between pulses, preserving pulsatile secretion.
Dose and Side Effect Relationship
The relationship between dose and side effects is a key consideration with GHRP-2:
- 100 mcg: Reliable GH stimulation with minimal cortisol and prolactin elevation.
- 200 mcg: Greater GH peak with moderate cortisol and prolactin increases.
- 300 mcg: Near-maximal GH response; cortisol and prolactin elevation becomes more clinically significant. GH response may plateau above this dose.
- >300 mcg: Diminishing returns for GH release with increasing side effect burden. Generally not recommended.
Cycling Patterns
- Continuous use: Some protocols use GHRP-2 daily without cycling, with the rationale that endogenous GH production is being stimulated (not suppressed) and the GH axis remains functional.
- 5 days on / 2 days off: A commonly reported cycling pattern intended to minimize potential receptor desensitization.
- Periodic breaks: Some providers recommend 4–8 week on / 2–4 week off cycling to maintain GHS-R1a sensitivity.
Storage
- Lyophilized powder: Store refrigerated (2–8°C / 36–46°F). Stable for months when kept dry and cold.
- Reconstituted solution: Refrigerate and use within 3–4 weeks. Do not freeze. Discard if solution becomes cloudy or discolored.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Results: What Users Report
The following timeline is compiled from clinician reports, patient surveys, and online communities — not from randomized controlled trials. Individual experiences vary significantly. GHRP-2 has not been evaluated for therapeutic efficacy in Phase 3 human trials.
Reported Timeline
| Timepoint | What Users Typically Report |
|---|---|
| Days 1–3 | Increased appetite (onset within 20–30 minutes of administration). Some users report improved sleep depth and more vivid dreams from the first night. Transient flushing or tingling at the injection site. |
| Week 1–2 | Consistent sleep improvement reported by a majority of users. Increased appetite becomes predictable. Some report improved skin hydration and a subjective sense of improved recovery from exercise. |
| Week 2–4 | Improved exercise recovery and reduced muscle soreness. Early body composition changes may be noticeable (reduced water retention fluctuation, improved muscle fullness). Increased energy and sense of well-being reported. |
| Week 4–8 | More visible body composition changes: reduction in subcutaneous fat, improved muscle tone. Enhanced recovery from training. Some users report improved joint comfort and skin quality. |
| Week 8–12+ | Body composition improvements continue to accrue. IGF-1 levels typically plateau. Some users report diminishing subjective effects, possibly reflecting receptor adaptation. |
Measurable Outcomes
Unlike many peptides where results are primarily subjective, GHRP-2's effects can be objectively measured:
- Serum GH levels: Acute GH peaks can be confirmed via timed blood draws after administration.
- IGF-1 levels: Sustained IGF-1 elevation (typically 20–50% above baseline) can be confirmed via standard laboratory testing after 2–4 weeks of consistent use.
- Body composition: DEXA scanning can objectively measure changes in lean mass and fat mass over 8–12 week periods.
What "Results" Means Without Phase 3 Data
While GHRP-2 has stronger pharmacokinetic/pharmacodynamic human data than many peptides (confirmed GH and IGF-1 elevation), the translation of these hormonal changes to specific clinical outcomes (body composition, recovery, anti-aging) has not been validated in large controlled trials. Key considerations:
- Hormonal elevation ≠ clinical benefit: Confirmed GH and IGF-1 increases do not automatically translate to meaningful improvements in body composition, recovery, or longevity.
- Placebo and expectation effects: Subjective reports of improved sleep, energy, and well-being are susceptible to placebo effects.
- Individual variability: GH response to GHRP-2 varies significantly based on age, body fat percentage, baseline GH status, and individual receptor sensitivity.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Side Effects
Reported Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Increased appetite | Common | Onset within 20–30 minutes post-administration. Mediated through ghrelin receptor activation. More pronounced than Ipamorelin, less than GHRP-6. |
| Water retention | Common | GH-mediated sodium and water retention. Typically mild and dose-dependent. May manifest as puffy fingers, tight rings, or mild ankle swelling. |
| Cortisol elevation | Common (dose-dependent) | Transient increase in cortisol levels. Minimal at 100 mcg; more significant above 200–300 mcg. Chronic elevation could theoretically affect metabolic parameters (Bowers et al., 1998). |
| Prolactin elevation | Uncommon-common | Mild, transient prolactin increase. Typically not clinically significant at standard doses. Monitor with chronic high-dose use (Arvat et al., 2001). |
| Tingling / flushing | Common | Transient paresthesias or warmth, particularly in the face and extremities, within minutes of administration. |
| Dizziness / lightheadedness | Uncommon | Typically mild and transient. May relate to transient blood pressure changes. |
| Injection site reaction | Uncommon | Mild redness, swelling, or tenderness. Typically resolves within hours. |
| Headache | Uncommon | Mild, self-limiting. More common during initial use. |
| Joint pain / carpal tunnel symptoms | Rare | Associated with elevated GH/IGF-1 levels. More likely with higher doses or prolonged use. Dose reduction typically resolves symptoms. |
Cortisol and Prolactin: Clinical Significance
The cortisol and prolactin elevation produced by GHRP-2 is a distinguishing characteristic compared to more selective GH secretagogues. Clinical considerations:
- Cortisol: Acute, transient cortisol elevations from individual GHRP-2 doses are generally well-tolerated. The concern is whether chronic, repeated cortisol stimulation could contribute to metabolic effects (insulin resistance, visceral fat accumulation, immune suppression) over time. This has not been systematically studied in long-term GHRP-2 use.
- Prolactin: Chronic prolactin elevation can theoretically affect reproductive function, libido, and mood. At standard GHRP-2 doses, prolactin elevation is typically modest and transient. Monitoring prolactin levels during extended use is a reasonable precaution.
Theoretical Risks
- GH/IGF-1 and cancer: Elevated GH and IGF-1 levels have been associated with increased cancer risk in epidemiological studies. Whether the intermittent GH elevation produced by GHRP-2 carries the same risk as sustained GH elevation (as in acromegaly) is unknown. Individuals with active malignancies or strong cancer risk factors should exercise caution.
- Insulin resistance: GH has anti-insulin effects. Chronic GH elevation through GHRP-2 use could theoretically worsen insulin sensitivity, particularly in individuals with pre-existing metabolic conditions.
- Receptor desensitization: Chronic GHS-R1a stimulation may lead to receptor downregulation and diminished GH response over time.
- Long-term safety: No long-term human safety data from controlled trials exists for chronic GHRP-2 use.
Drug Interactions
- Glucocorticoids: Exogenous corticosteroid use may blunt the GH response to GHRP-2 and compound cortisol-related side effects.
- Insulin / diabetes medications: GH opposes insulin action. Individuals on insulin or oral hypoglycemics should monitor blood glucose closely.
- Dopamine agonists: Cabergoline and bromocriptine (used for prolactin management) may interact with GHRP-2's prolactin-elevating effects.
- Somatostatin analogs: Octreotide and similar agents suppress GH release and would directly antagonize GHRP-2's mechanism of action.
Contraindications
- Active cancer or recent cancer history — due to GH/IGF-1 mitogenic properties
- Pregnancy and breastfeeding — no safety data available
- Uncontrolled diabetes — GH antagonizes insulin action
- Active pituitary tumors — GHS-R1a stimulation in pituitary tissue
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Regulatory Status
Regulatory Status by Jurisdiction
| Jurisdiction | Status | Details |
|---|---|---|
| Japan | Approved (diagnostic) | Approved as pralmorelin for GH deficiency diagnosis. Marketed under regulatory oversight with quality-controlled pharmaceutical-grade product. |
| United States (FDA) | Not approved | No FDA approval for any indication. Not currently listed on FDA compounding bulk substance categories. Available through research chemical suppliers. |
| European Union (EMA) | Not approved | No EMA marketing authorization. Available through research channels. |
| WADA | Prohibited | Listed under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Prohibited at all times, in- and out-of-competition. |
WADA Prohibition
GHRP-2 is specifically named on the WADA Prohibited List under category S2. Unlike some peptides that fall under the general S0 (non-approved substances) category, GHRP-2 is explicitly identified as a growth hormone secretagogue. Detection methods for GHRP-2 and its metabolites in urine have been developed and validated, and positive tests have resulted in anti-doping sanctions (WADA Prohibited List).
Research Chemical Market
In the United States and most Western countries, GHRP-2 is primarily available through research chemical suppliers. These products are:
- Labeled "for research purposes only" or "not for human consumption"
- Not subject to FDA drug manufacturing standards (cGMP)
- Variable in quality, with independent analyses showing inconsistent purity across suppliers
- Sold in a regulatory gray area — not marketed as drugs for human use
Legal Status
GHRP-2 is not a scheduled or controlled substance in the United States or most other countries. It is legal to purchase and possess in most jurisdictions. However:
- Selling GHRP-2 for human therapeutic use without regulatory approval would violate FDA regulations
- Use by competitive athletes subject to WADA testing constitutes a doping violation
- Regulatory classification may change; the peptide regulatory landscape is evolving
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Cost
Typical Pricing
| Source | Typical Price Range | What You Get | Quality Assurance |
|---|---|---|---|
| Research chemical supplier (US) | $30–$80 per 5mg vial | Lyophilized powder, labeled "for research only." Buyer reconstitutes independently. | Variable — some suppliers provide certificates of analysis (COAs); quality varies between suppliers. |
| Peptide specialty vendor | $50–$120 per 5mg vial | Higher-purity lyophilized powder with third-party testing documentation. | Moderate-high — vendors providing HPLC and mass spectrometry analysis of individual batches. |
| Telehealth / anti-aging clinic | $200–$400/month (all-inclusive) | Provider consultation, prescription, compounded product, and monitoring. Availability varies by clinic and current regulatory status. | Highest — medical oversight with laboratory monitoring. |
Monthly Cost Estimate
| Protocol | Monthly Peptide Cost | Notes |
|---|---|---|
| 200 mcg 2x daily (research supplier) | $100–$160 | Approximately 12mg/month. 2–3 vials at typical research pricing. |
| 200 mcg 2x daily (premium supplier) | $150–$250 | Same usage, higher per-vial cost with better quality documentation. |
| Combined GHRP-2 + GHRH analog | $200–$400 | Adding a GHRH analog (CJC-1295 or mod GRF 1-29) increases total peptide cost. |
Insurance Coverage
GHRP-2 is not covered by any insurance plan. It has no FDA-approved indication and cannot be billed under any drug, medical, or prescription benefit. All costs are out-of-pocket. This includes the peptide itself, supplies, provider consultations, and monitoring bloodwork (though bloodwork may be partially covered under general laboratory benefits).
Additional Costs
- Bacteriostatic water: $5–$15 per vial (required for reconstitution)
- Supplies: $10–$20/month (insulin syringes, alcohol swabs)
- Provider consultation: $100–$300 (initial), $50–$150 (follow-up) at anti-aging/regenerative clinics
- Blood work (IGF-1, GH, cortisol, prolactin, metabolic panel): $100–$400 per panel (varies by insurance coverage and lab)
Cost Comparison: GHRP-2 vs. Alternatives
| Treatment | Typical Monthly Cost | Insurance |
|---|---|---|
| GHRP-2 (research) | $100–$250 | Not covered |
| Ipamorelin (research) | $120–$280 | Not covered |
| GHRP-6 (research) | $100–$250 | Not covered |
| Recombinant HGH (pharmaceutical) | $800–$3,000+ | Covered for approved indications only |
| Sermorelin (compounded) | $200–$500 | Rarely covered |
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Questions & Answers
Myth: GHRP-2 is basically the same as taking HGH.
Answer: GHRP-2 stimulates the body's own GH production; it does not introduce exogenous growth hormone. The GH released in response to GHRP-2 follows a pulsatile pattern that mimics (and amplifies) natural secretion. Exogenous HGH injections deliver a bolus of GH that does not replicate physiologic pulsatility and can suppress endogenous GH production through negative feedback. The magnitude of GH elevation from GHRP-2 is also substantially lower than typical therapeutic HGH doses (Bowers, 2001).
Myth: GHRP-2 is a steroid.
Answer: GHRP-2 is a synthetic peptide — a chain of 6 amino acids. It has no structural or mechanistic relationship to anabolic-androgenic steroids. It does not increase testosterone, does not have androgenic effects, and does not work through androgen receptor pathways. Its effects are mediated entirely through the GH/IGF-1 axis via ghrelin receptor activation (Bowers et al., 1998).
Myth: GHRP-2 and Ipamorelin are interchangeable.
Answer: While both are GH secretagogues that activate the ghrelin receptor, they have different selectivity profiles. Ipamorelin is more selective — it stimulates GH release with minimal effect on cortisol and prolactin. GHRP-2 is more potent for GH stimulation but also elevates cortisol and prolactin, particularly at higher doses. The choice between them involves a trade-off between potency and selectivity (Arvat et al., 2001).
Myth: GHRP-2 will make you huge.
Answer: The GH elevation produced by GHRP-2 is meaningful but modest compared to supraphysiologic HGH dosing used in some bodybuilding contexts. GHRP-2 supports body composition improvement (modest fat loss, lean mass preservation) rather than dramatic muscle hypertrophy. It is not a substitute for training, nutrition, or anabolic agents for individuals seeking significant muscle growth.
Myth: GHRP-2 suppresses your natural GH production.
Answer: GHRP-2 stimulates endogenous GH release from the pituitary — it does not introduce exogenous GH. The pituitary gland produces its own GH in response to GHRP-2's receptor activation. There is no documented suppression of GH production after GHRP-2 discontinuation comparable to the HPA axis suppression seen with exogenous corticosteroids. Some degree of GHS-R1a desensitization with chronic use is possible, but this is receptor adaptation, not GH axis suppression (Bowers, 2001).
Myth: All peptide suppliers sell the same product.
Answer: Independent analyses of peptide products from research chemical suppliers have found significant variability in purity, potency, and the presence of degradation products or contaminants. Some products contain substantially less active peptide than labeled. Source, third-party testing, and certificates of analysis matter.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Key Takeaways
Based on the available evidence:
- GHRP-2 is a synthetic hexapeptide that stimulates endogenous growth hormone release via activation of the ghrelin receptor (GHS-R1a). It is one of the most potent members of the GHRP family of growth hormone secretagogues.
- It has Phase 1–2 human data demonstrating reliable GH stimulation, and is approved in Japan for diagnostic evaluation of GH deficiency. No Phase 3 therapeutic trials have been completed.
- GHRP-2 is less selective than Ipamorelin, producing dose-dependent elevations in cortisol and prolactin in addition to GH. This trade-off between potency and selectivity is a key consideration in choosing between GH secretagogues.
- It is not FDA-approved for any therapeutic indication. It is available primarily through research chemical suppliers in the United States and most Western countries.
- Common side effects include increased appetite, water retention, flushing, and transient cortisol/prolactin elevation. Side effects are dose-dependent and generally manageable.
- Cost ranges from $100–$250/month through research chemical suppliers, and is not covered by insurance.
- WADA prohibits GHRP-2 under category S2 (Peptide Hormones, Growth Factors). Detection methods are established and in use.
Who Might Consider GHRP-2
Based on the available evidence and clinical practice patterns, GHRP-2 may be worth discussing with a healthcare provider for individuals who:
- Have documented age-related GH decline and are seeking alternatives to exogenous GH therapy
- Want to enhance GH-mediated recovery from exercise or injury
- Are interested in GH secretagogue therapy and prioritize GH potency over side effect minimization
- Have access to a knowledgeable provider who can prescribe, monitor, and manage hormonal side effects appropriately
- Are willing to undergo baseline and follow-up blood work (IGF-1, cortisol, prolactin, metabolic panel)
- Understand that the evidence base is largely Phase 1–2 and accept the associated uncertainty
Questions to Ask a Provider
- Is GHRP-2 or a more selective GH secretagogue (Ipamorelin) more appropriate for my goals?
- What dose and frequency do you recommend, and how will you monitor for cortisol and prolactin effects?
- Should I combine GHRP-2 with a GHRH analog for synergistic effects?
- What baseline blood work should I have before starting?
- What monitoring schedule is appropriate during treatment?
- Are there any interactions with my current medications?
- Where will the GHRP-2 be sourced, and what quality testing has been performed?
- What is the expected duration of use, and should I cycle on and off?
This content is for informational and educational purposes only. It is not intended as, and should not be interpreted as, medical advice. The information provided does not cover all possible uses, precautions, interactions, or adverse effects, and may not reflect the most recent medical research or guidelines. It should not be used as a substitute for the advice of a qualified healthcare professional. Never disregard professional medical advice or delay seeking treatment because of something you have read here. Always speak with your doctor or pharmacist before starting, stopping, or changing any prescribed medication or treatment. If you think you may have a medical emergency, call your doctor or emergency services immediately. GLPbase does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Use of this information is at your own risk.
Sources & Further Reading
Comprehensive Reviews & Pharmacology
- Bowers et al. (1998) — "Unnatural growth hormone-releasing peptide begets natural ghrelin" — Journal of Clinical Endocrinology & Metabolism
- Bowers (2001) — "Selective growth hormone secretagogues" — Hormone Research
- Muccioli et al. (2007) — "Neuroendocrine and peripheral activities of ghrelin" — Frontiers in Neuroendocrinology
Human Clinical Studies
- Arvat et al. (2001) — "Endocrine activities of ghrelin, a natural growth hormone secretagogue, in humans" — Journal of Clinical Endocrinology & Metabolism
- Broglio et al. (2003) — "GH secretagogue activity of GHRP-2 in elderly subjects" — Journal of Endocrinological Investigation
- Kojima et al. (2006) — "Pralmorelin (GHRP-2) for diagnostic use in GH deficiency" — Endocrine Journal
Mechanism of Action
- Bowers et al. (1998) — GHS-R1a receptor activation and signaling
- Bowers (2001) — GHRH synergy and pulsatile GH secretion
- Muccioli et al. (2007) — Ghrelin receptor biology and appetite regulation
Cardioprotection
Regulatory & Classification
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
